AU2003294668A8 - Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas - Google Patents

Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas

Info

Publication number
AU2003294668A8
AU2003294668A8 AU2003294668A AU2003294668A AU2003294668A8 AU 2003294668 A8 AU2003294668 A8 AU 2003294668A8 AU 2003294668 A AU2003294668 A AU 2003294668A AU 2003294668 A AU2003294668 A AU 2003294668A AU 2003294668 A8 AU2003294668 A8 AU 2003294668A8
Authority
AU
Australia
Prior art keywords
liposarcomas
jnk
diagnosis
inhibitors
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003294668A
Other versions
AU2003294668A1 (en
Inventor
Alain Aurias
Frederic Chibon
Odette Mariani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie Paris 6
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Curie
Original Assignee
Universite Pierre et Marie Curie Paris 6
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Pierre et Marie Curie Paris 6, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Curie filed Critical Universite Pierre et Marie Curie Paris 6
Publication of AU2003294668A1 publication Critical patent/AU2003294668A1/en
Publication of AU2003294668A8 publication Critical patent/AU2003294668A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003294668A 2002-09-06 2003-09-05 Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas Abandoned AU2003294668A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02292195.1 2002-09-06
EP02292195 2002-09-06
PCT/EP2003/009867 WO2004026407A1 (en) 2002-09-06 2003-09-05 Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas

Publications (2)

Publication Number Publication Date
AU2003294668A1 AU2003294668A1 (en) 2004-04-08
AU2003294668A8 true AU2003294668A8 (en) 2004-04-08

Family

ID=31502838

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003294668A Abandoned AU2003294668A1 (en) 2002-09-06 2003-09-05 Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas

Country Status (2)

Country Link
AU (1) AU2003294668A1 (en)
WO (1) WO2004026407A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005114199A1 (en) * 2004-05-13 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 5 (map3k5)
EP2411516A1 (en) * 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514745B1 (en) * 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
JP3839103B2 (en) * 1996-04-19 2006-11-01 財団法人癌研究会 Apoptosis-inducing protein and gene encoding the same
CN1302107C (en) * 1998-01-30 2007-02-28 吉倪塞思技术公司 Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
US6080546A (en) * 1999-07-23 2000-06-27 Isis Pharmaceuticals Inc. Antisense modulation of MEKK5 expression
WO2001080849A1 (en) * 2000-04-26 2001-11-01 Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Method of treating cancer
KR100399982B1 (en) * 2000-06-16 2003-11-13 학교법인고려중앙학원 Novel mouse CIA protein and CIA gene having anti-apoptotic activity as a selective inhibitor of CAD interacting with ASK1 and use thereof
JP2002069005A (en) * 2000-08-30 2002-03-08 Japan Science & Technology Corp Solid carcinoma-curing formulation
AU2001291235A1 (en) * 2000-09-25 2002-04-08 Millenium Pharmaceuticals, Inc. 22108 and 47916, novel human thioredoxin family members and uses thereof
WO2002048168A1 (en) * 2000-10-24 2002-06-20 Isis Pharmaceuticals, Inc. Antisense modulation of tnfr1 expression

Also Published As

Publication number Publication date
WO2004026407A1 (en) 2004-04-01
AU2003294668A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
HK1079426A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
IL174431A0 (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
HK1067945A1 (en) Substituted benzazoles and use thereof as raf kinase inhibitors
AP2334A (en) Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
NO20042147L (en) Heterocyclic compounds and processes for their use
EE200300227A (en) Methods for the Treatment of P38 Kinase Related Conditions and Pyrrolotriazine Compounds Useful as Kinase Inhibitors
EP1758854A4 (en) Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
HK1067362A1 (en) Heterocyclic compounds for use in the treatment ofdisorders of the urinary tract
PL1838301T3 (en) Use of resiniferatoxin (rtx) for the preparation of an agent for the treatment of pain
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
IS7970A (en) PDE4 inhibitors for the treatment of lymphoma
IL172126A0 (en) Nitrogen-containing heteroaryl derivatives for the treatment of hcv-infection
EP1832875A4 (en) Biological microchip for multiple parallel immunoassay of compounds and immunoassay methods using said microchip
IL161748A0 (en) New use for the treatment of gastroesophageal reflux
AU2003294668A8 (en) Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas
GB0415181D0 (en) Compounds for use in the treatment of infection
AU2003270683A8 (en) Compounds for the treatment of premature ejaculation
AU2003205452A8 (en) Bmp inhibitors for the treatment of spondyloarthropathies
GB2410744B (en) Kinase inhibitors for the treatment of disease
IL178907A0 (en) Use of sulglicotide for the treatment of mucositis
IS8498A (en) Use of cathepsin K inhibitors for the treatment of severe bone loss disorders
EP1804805A4 (en) Use of aromatase inhibitors for the treatment of ectopic pregnancy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 19, PAGE(S) 5408 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME INSTITUT CURIE, APPLICATION NO. 2003294668, UNDER INID (71) CORRECT THE NAME TO READ INSTITUT CURIE; UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM